Blood Gas Analyzer Companies

The blood gas analyzer market is expected to be valued at USD 2.70 billion in 2025 and projected to reach USD 3.38 billion by 2030, expanding at a CAGR of 4.6% during the forecast period. Market growth is primarily driven by the increasing prevalence of chronic and acute diseases, such as respiratory disorders, cardiovascular conditions, and diabetes, which require frequent and precise monitoring of patients’ blood gas levels. Additionally, advancements in point-of-care testing technologies are enabling faster, real-time diagnostics in critical care units, improving patient outcomes. The rising awareness of early detection and disease management is further accelerating demand. Government initiatives promoting modern diagnostic infrastructure and investment in healthcare facilities contribute significantly to the market’s expansion.

In July 2024, Werfen S.A. (Spain) launched the GEM Premier 7000 with Intelligent Quality Management 3 (iQM3) after receiving 510(k) clearance from the US Food and Drug Administration. The GEM Premier 7000 with iQM3 is the first point-of-care (POC) system to offer hemolysis detection, enhancing the reliability of blood gas testing. In May 2024, Danaher Corporation (US) partnered with Etiometry (US), a clinical decision-support software provider, to improve decision-making and workflows in critical care. Through the integration of the Etiometry platform with Radiometer’s acute care diagnostics, clinicians can view blood gas results together with physiological parameters and other essential clinical data on a unified interface.

The key players in this market are Danaher Corporation (US), Werfen S.A. (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Nova Biomedical (US), Medica Corporation (US), Techno Medica Co., Ltd. (Japan), IDEXX Laboratories, Inc. (US), i-SENS, Inc. (South Korea), EDAN Instruments, Inc. (China), Guangzhou Wondfo Biotech Co., Ltd. (China), Labtron Equipment Ltd. (UK), Convergent Technologies GmbH & Co. KG (Germany), Erba Group (Czech Republic), ESCHWEILER GmbH & Co. KG (Germany), Sensa Core Medical Instrumentation Pvt. Ltd. (India), Chengdu Seamaty Technology Co., Ltd. (China), Labdex Ltd. (UK), Meizhou Cornley High-Tech Co., Ltd. (China), Paramedical Srl (Italy), Eaglenos Sciences, Inc. (China), B&E Bio-technology Co., Ltd. (US), Labnics Ltd. (UK) and Fison Instruments Ltd. (UK).

To know about the assumptions considered for the study download the pdf brochure

Danaher Corporation (US) is a leading player in the blood gas analyzer market due to its extensive global network and well-integrated operations, which allow the company to address diverse disease testing needs across multiple regions. Its robust distribution and service infrastructure ensure reliable product availability even in dynamic market conditions. Furthermore, the company strengthens its market leadership through strategic collaborations and partnerships that enhance its technological capabilities and expand its presence in high-growth segments of the diagnostics industry.

Werfen is one of the leading players in the blood gas analyzer market, driven by its innovative product portfolio and focus on advanced point-of-care solutions. Its strong global presence and efficient distribution network ensure timely access to its analyzers across diverse healthcare settings. Its continuous investment in research and development enables the introduction of new technologies and features that improve testing speed, reliability, and overall patient care.

Market Ranking

The blood gas analyzer market is highly competitive, with the top five players collectively holding the total market share.

Danaher Corporation (US) strengthens its leadership in the blood gas analyzer market by offering scalable and automated diagnostic platforms that support high-throughput testing and diverse critical care applications. Werfen S.A. (Spain) maintains a strong position through advanced point-of-care analyzers, a global distribution network, and continuous investment in innovative features that enhance testing speed, reliability, and operational efficiency. F. Hoffmann-La Roche Ltd. (Switzerland) is leading with integrated blood gas and critical care solutions, leveraging global reach, regulatory expertise, and ongoing technological innovation. Abbott Laboratories (US) contributes significantly with a comprehensive analyzer portfolio emphasizing point-of-care efficiency, automation, and connectivity to support rapid clinical decision-making. Siemens Healthineers AG (Germany) is a key player with advanced blood gas analyzers and integrated diagnostics platforms, backed by a strong global presence, robust service infrastructure, and a focus on innovative solutions for critical and emergency care settings.

Related Reports:

Blood Gas Analyzer Market by Product (Consumables, Services), Type of Testing (PoC, Conventional), Sample (Arterial, Venous, Capillary Blood), Application (Respiratory, Emergency Care Management), End User (Hospitals, Clinics) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com